May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
4th Generation Fluoroquinolone Penetration into Aqueous Humor in Humans
Author Affiliations & Notes
  • J.P. McCulley
    Ophthalmology, Univ of TX Southwestern–Dallas, Dallas, TX
  • G. Surratt
    Ophthalmology, Univ of TX Southwestern–Dallas, Dallas, TX
  • W. Shine
    Ophthalmology, Univ of TX Southwestern–Dallas, Dallas, TX
  • Footnotes
    Commercial Relationships  J.P. McCulley, Alcon Laboratories, Inc. C, R; G. Surratt, None; W. Shine, None.
  • Footnotes
    Support  Supported in part by an unrestricted grant from RPB
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 4927. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J.P. McCulley, G. Surratt, W. Shine; 4th Generation Fluoroquinolone Penetration into Aqueous Humor in Humans . Invest. Ophthalmol. Vis. Sci. 2004;45(13):4927.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To compare directly penetration of two 4th generation fluoroquinolones (FQ) [moxifloxacin and gatifloxacin], into aqueous humor (AH) in humans after topical application and to published levels for 2nd and 3rd generation FQs. Methods: Patients scheduled for routine phacoemulsification and IOL insertion who were otherwise without ocular disease, were given, in a double masked fashion, either commercial moxifloxacin 0.5% (VigamoxTM) or gatifloxacin 0.3% (ZymarTM) to use q.i.d. the day before surgery and one hour prior to the surgical entry into the anterior chamber on the day of surgery. AH samples were taken and chromatographically analyzed by HPLC. AH FQ concentration was calculated by peak comparison to a known concentration peak for ciprofloxacin which was run as an internal standard. These were compared to published concentration of other available FQs. Results: Moxifloxacin AH concentration was 2.01 Fg/ml and gatifloxacin was 1.02 Fg/ml. Published values after q.i.d. dosing for ciprofloxacin 0.3% are 0.07 Fg/ml, levofloxacin 0.5% are 0.28 Fg/ml but are not available for ofloxacin with q.i.d. dosing. Conclusions: AH antibiotic concentration achieved at the time of cataract surgery after topical application serves as an effective surrogate for what can be achieved with typical post–operative topical dosing, e.g. q.i.d. Both 4th generation FQs achieved superior AH concentration after q.i.d. dosing compared to prior generation FQs with moxifloxacin achieving twice the concentration of gatifloxacin. The superior and clinically significant penetration of moxifloxacin into the AH can be partially attributed to its greater solubility at neutral pH and greater concentration in the commercial preparation.

Keywords: antibiotics/antifungals/antiparasitics • aqueous • endophthalmitis 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×